FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

BIOCON Share Price Discussion

Biocon Ltd.
Sector: Pharmaceuticals and health care
... Read more
BIOCON Share Price *
288.95 +2.35 (0.82%)
* (quote may be delayed)

Find answers to all your questions on live BIOCON message board: Is BIOCON buy or sell? Should I buy BIOCON shares? Why are BIOCON shares falling? Should I invest in BIOCON stock?


You can also check BIOCON share price target recommended by brokerages.

BIOCON Discussion Forum


Performance for the WEEK*
Futures & Options educational trades for the week 2.12.19 to 6.12.19*
BIOCON CE 280* cmp 13.00 buy upto 7.00 stop 4.00 target 27.00+
Entry 13.50 to 23.00
*profit ₹ 17100*
Like
reply
Reply
share
Share

BIOCON - chart - 468981
#Biocon trying to come below its Support. #BSE #SENSEX #NIFTY
Like
reply
Reply
share
Share

05-12-19
BIOCON SELL FUT DEC (Intraday)
only below @ 285.40
Like
reply
Reply (3)
share
Share
Latest replies
Sameer  @tradingfab
Dec 5 4:15 PM

LOW 285 *****************
Sameer  @tradingfab
Dec 5 4:23 PM

LOW 284.80 **************
Sameer  @tradingfab
Dec 5 5:05 PM

LOW 284.50 **********************

BIOCON - 465116
BIOCON
Entry 13.50 to 23.00 (cmp 15.40)
*profit ₹ 17100*
Like
reply
Reply
share
Share
Q. Any view on biocon
Like
reply
Reply (9)
share
Share
Latest replies
Invictus @invictotrader
Dec 3 3:43 PM

If it sustained 288-291 then buy risky call
Invictus @invictotrader
Dec 3 4:03 PM

One thing keep in mind, buy the rumours sell the news, when there is any news on particular company just avoid.
Invictus @invictotrader
Dec 3 4:57 PM

Making support, healthy living sign
HIDDEN GEM @hidden
Dec 4 1:17 AM

SHORT BIOCON 290-300 WITH SL 308 POSITIONAL TGTS 272-248**
Profitmaker @Profitmaker
Dec 4 1:42 AM

320 act as a major resisitance for this month we can sell from this level

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY BIOCON AT THE VERY BEGINING
STRICT STOP LOSS - 280.95
TARGET - 289/291/293
## AVOID IF IT OPEN 3% AND HIGHER##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please consult with your financial a...
Read more...
Like
reply
Reply
share
Share

Biocon and Mylan announced the launch of Ogivri M, a biosimilar to Herceptin, in the U.S.
Like
reply
Reply
share
Share

BIOCON - 463712

Like
reply
Reply
share
Share

HSBC on Biocon
Biocon & partner Mylan launched Ogivri (biosimilar
trastuzumab) in US
Ogivri is well set to grab market share on flexible dosage
offering, supported by co’s robust manufacturing setup
Gaining favourable formulary coverage will be
Buy; TP raise to Rs 325 (Vs Rs 280)
Like
reply
Reply
share
Share

MS On Biocon
OW, TP Rs 350
Launched Biosimilar Trastuzumab In US As Per Terms Of Its Settlement
It’s 2nd Biosimilar Launch & Each Pdt Was An Early Entrant In Mkt
Importantly, Management Has Reiterated Its $1 Bn Biosimilar Sales Tgt For F22
Like
reply
Reply
share
Share
Hustle With Ichimoku in BIOCON
Biocon buy given at 265..... 280 done. Now nex...

BIOCON - 463384
Biocon great news. Now 320 is confirmed easily #ichimoku #biocon
Like
reply
Reply
share
Share
Hustle With Ichimoku in BIOCON
Biocon 280 made

BIOCON - 463342
Biocon buy given at 265..... 280 done. Now next level 320 #biocon #ichimoku
Like
reply
Reply
share
Share

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA Ogivri was the first biosimilar of Herceptin to be approved by USFDA two years ago, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.
Like
reply
Reply
share
Share

BIOCON - chart - 463170
# BIOCON OVERVIEW
Biocon target 300 and find support at 280
Like
reply
Reply
share
Share

288 ENTERING SOON
Like
reply
Reply
share
Share

Futures & Options educational trades for the week 2.12.19 to 6.12.19*
(My trade rules apply)
BIOCON CE 280* cmp 13.00 buy upto 7.00 stop 4.00 target 27.00+
Sridhar Balakrishnan
Ping me for more
1
reply
Reply
share
Share
Q. Biocon dec future @283.2, pls suggest SL, Taget ?
Like
reply
Reply (6)
share
Share
Latest replies

Ok thanks
vijay jaria @vijayjaria
Nov 30 11:11 PM

Main Support at 252-254
Main resistance 286-293
Chart looks positive and it may hit new high but as rally is fast so for some days it may be sideways or profit booking may come .
There are other support in between but main support is 252-254
vijay jaria @vijayjaria
Nov 30 11:12 PM

Above closing on resistance of 286-293 it may move to hit new high
Invictus @invictotrader
Dec 1 2:15 AM

As per future data short build-up,
As per options data 290 strong and 300 will be very strong resistance,
As per chart For now 270 support, 260 very strong support for now, and as it clearly got rejection from previous support if it sustained at this level then only buy will ta...
Invictus @invictotrader
Dec 1 2:25 AM

BIOCON - 461721
When a support become the resistance it means there is strong seller at the level, if it sustained at the level then only buy zone

BIOCON - chart - 458783
Biocon
Another Blockbuster Mover bought at open on Monday near 256 achieved both Target 270 and 280 within 3 days. We booked 75% and holding balance with Trailing Stop loss. Made high 282.95 today almost 10%+ from Entry.
#TradeAdda
Like
reply
Reply
share
Share

BIOCON - 458133

1
reply
Reply
share
Share

CLSA on Biocon
US FDA approved incremental capacities for co’s biosimilar Pegfilgrastim
This is on expected lines & part of our forecasts for FY20-22
With competition expected to rise in this product, window to gain share would be limited
Sell, TP Rs 210
Like
reply
Reply
share
Share
Hustle With Ichimoku in BIOCON
Biocon 265 target 280 ( holding myself from 2...

Biocon 280 made
Like
reply
Reply
share
Share
Intraday Cash Trades in BIOCON
Buy-276 T-280 Sl-273

BIOCON - 457334

Like
reply
Reply
share
Share
Santosh Gupta in BIOCON
FNO: BUY BIOCON ABV 275

ONCE BOOK AND EXIT LONG IN BIOCON AT 277, PROFIT RS 3600.
Like
reply
Reply
share
Share

Biocon
TGT 3 284.9
TGT 2 281.9
TGT 1 278.9
SL 269.5
1
reply
Reply
share
Share

Biocon:
Biocon Surges After U.S. FDA Approval For Pegfilgrastim Drug From New UnitShares of Biocon Ltd. rose as much as 5.50 percent to Rs 278.50 apiece, the highest since Jun. 4, 2019.
The United States Food and Drug Administration, or U.S. FDA, has approved Biocon and Mylan's s...
Read more...
2
reply
Reply
share
Share
TradeAdda in BIOCON
Biocon #Nse #Bse #equity #Positional #TradeAdd...

Biocon
Made high 279.30 almost within touching of T2 280 book 75% now and Trail remaining.
#TradeAdda
Like
reply
Reply (2)
share
Share
Latest replies
Sanjay Gupta @sanjaygupta
Nov 27 4:04 PM

Any new target ...I am holding this at 274?
TradeAdda @nishantshah91
Nov 27 7:02 PM

Seeing some resistance near 280 so my advice sell and wait for close above 280 then target will be 300/320 Sl 263.90

🔬🔬BIOCON💉💉💉 future first target🎯🎯 done made a high 279.25book partially profit
Like
reply
Reply
share
Share
#Hansraj pandey in BIOCON
BUY BIOCON FUT @ 273,-74 STOP LOSS 271 TARGET 2...

🔬🔬BIOCON💉💉💉 future first target🎯🎯 done made a high 279.25book partially profit
Like
reply
Reply
share
Share

Not liquid but interesting setup in #optionchain for #Biocon
Like
reply
Reply
share
Share

Buy-276
T-280
Sl-273
1
reply
Reply
share
Share

BUY BIOCON FUT @ 273,-74 STOP LOSS 271 TARGET 277 / 282+
Like
reply
Reply
share
Share

BUY BIOCON FUT @ 273,-74 STOP LOSS 271 TARGET 277 / 282+
1
reply
Reply
share
Share

FNO: BUY BIOCON ABV 275
Like
reply
Reply
share
Share
TradeAdda in BIOCON
Biocon #Nse #Bse #equity #Positional #TradeAdd...

Biocon
Made high 276 from 256 bought on Monday almost near T2 280 now. Keep Booking super profits or trail super 20 points move.
#TradeAdda
Like
reply
Reply
share
Share

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY BIOCON AT THE VERY BEGINING
STRICT STOP LOSS - 262
TARGET - 266/269/276
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please consult with your financial adviser before any Trade. All Equity and...
Read more...
Like
reply
Reply
share
Share

BIOCON - chart - 454977
BIOCON
Super Move Made High 270 from 256.30 Made us wait but delivered the Goods. Target 1 270 done Now . Book Half and Trail Rest to cost.
#TradeAdda #biocon
Like
reply
Reply
share
Share
TradeAdda in BIOCON
Biocon #Nse #Bse #equity #Positional #TradeAdd...

Only 2% voted for Biocon but Now Biocon also moving nicely towards Target 1 270. New High 266.95 🚀 10 points/5 % plus move done in a day.
Like
reply
Reply
share
Share
TradeAdda in BIOCON
Biocon #Nse #Bse #equity #Positional #TradeAdd...

BIOCON
Super Move Made High 265.50 remember bought yesterday at 256.30 Move Started Now. Ready for Target 1 270.
#TradeAdda
1
reply
Reply
share
Share
TradeAdda in BIOCON
Biocon #Nse #Bse #equity #Positional #TradeAdd...

Biocon
Made high intraday 259.75 from open 256.30
#TradeAdda #biocon
Like
reply
Reply
share
Share

BIOCON - chart - 452282
Biocon
#Nse #Bse #equity #Positional #TradeAdda #stockmarket #breakout #bullish
For Educational Purposes only.
#TradeAdda
Like
reply
Reply (1)
share
Share
Latest replies
TradeAdda @nishantshah91
Nov 26 5:38 PM

BIOCON
Super Move Made High 268.50 from 256.30 Made us wait but delivered the Goods. Target 1 270 almost done Now . Book Half and Trail Rest to cost. Enjoy.
#TradeAdda #biocon

BIOCON GIVEN AT 263 YDAY
NOW MADE 257 + 6000
DERISK N HOLD
CHAPO INDIA CHAPO
Like
reply
Reply
share
Share

ENTERING AGAIN 257
Like
reply
Reply
share
Share
Calls Unlimited in BIOCON
BIOCON PATIENCE - PAYS 266 TO 259 + 7000 DERI...

BIOCON GIVEN AT 264
NOW MADE 250 + 14000
CHAPO INDIA CHAPO
Like
reply
Reply
share
Share
Calls Unlimited in BIOCON
BIOCON PATIENCE - PAYS 266 TO 259 + 7000 DERI...

BIOCON
FREE FALL
266 TO 258 + 8000
Like
reply
Reply
share
Share
Daily Winner in BIOCON
buy biocon sl 259.90 tgt 267.90 cmp 262.80

So gone ab reverse 257
Like
reply
Reply
share
Share
Calls Unlimited in BIOCON
266 WE WILL ENTER SHORT SOON

BIOCON
PATIENCE - PAYS
266 TO 259 + 7000
DERISK N HOLD
CHAPO INDIA CHAPO
Like
reply
Reply
share
Share

buy biocon sl 259.90 tgt 267.90 cmp 262.80
Like
reply
Reply
share
Share

buy biocon sl 259.90 tgt 267.90 cmp 262.80
Like
reply
Reply
share
Share

BIOCON - 432521
Biocon 265 target 280
( holding myself from 230 levels)
Investors can Ping me to know details on whatsapp
Like
reply
Reply
share
Share

Booked eqity 268
Like
reply
Reply
share
Share
  • BIOCON - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization36,660
    Enterprise Value36,305
    Price to Earnings149.8
    Price to Book Value5.15
    Return on Capital Employed0.04
    Return on Equity0.04
    Face Value5
    Dividend YieldNA
  • BIOCON Share Price - Technicals

    keyboard_arrow_down
    BIOCON - 52 Week High₹682.45
    BIOCON - 52 Week Low₹211.05
  • BIOCON - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    30-Oct-19Geojit Financial ServicesHold260
    24-Oct-19ICICIdirect.comBuy310
    24-Oct-19Nirmal BangAccumulate252
    2-Aug-19AnandRathiBuy321
    2-Aug-19Axis DirectBuy300
    BIOCON Brokerage Price Target
  • BIOCON Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 6288.05293.35286.05289
    Dec 5287.2289.25283.9286.6
    Dec 4284289281.15287.2
    Dec 3299299282.85285.7
    Dec 2283.2291.95282.45285.8
  • BIOCON Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹269.42
    30 Day Moving Average₹263.29
    50 Day Moving Average₹252.7
    100 Day Moving Average₹243.42
    200 Day Moving Average₹386.93
  • BIOCON - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,4252,587.9-0.06
    Operating Profit318591.8-0.46
    Profit Before Tax305536.2-0.43
    Net Income238519.3-0.54
  • BIOCON - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds7,1156,7370.06
    Total Liabilities1,1251,0450.08
    Total Assets8,2407,7830.06
  • BIOCON - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity355185.80.91
    Cash from Investing Activity-553104-6.32
    Cash from Financing Activity-54-238.3-0.77
    Net Cash Flow-25251.5-5.89
  • BIOCON - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.07
    Return on Equity0.040.08
    Return on Capital Employed0.040.08
  • BIOCON - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.08
    3 Year CAGR Growth in Operating Profit-0.22
    3 Year CAGR Growth in EBIDTA-0.21
    3 Year CAGR Growth in Net Income-0.34
    3 Yr CAGR Growth - Diluted EPS-0.78
  • BIOCON - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.25
    5 Year CAGR Growth in Operating Profit-0.18
    5 Year CAGR Growth in EBIDTANA
    5 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.71
  • BIOCON - Recent News

    keyboard_arrow_down
    NewsBot
    Oct 24 9:03 PM
    Biocon, Indian Bank decline 6-12% after Q2 earnings
    Moneycontrol
    NewsBot
    Oct 24 1:53 PM
    Market Headstart: Nifty50 seen opening higher; HCL Tech, Hero MotoCorp eyed
    Moneycontrol
    NewsBot
    Oct 24 2:18 AM
    Biocon Q2 net profit at Rs 216 cr
    Moneycontrol
    NewsBot
    Oct 12 5:08 PM
    Stock movers for the week: Bharti Airtel, Century Textiles, Bandhan Bank top the charts
    Moneycontrol
    NewsBot
    Oct 11 5:23 PM
    'Investors can deploy sell-on-rise stance for the coming week towards 11,400'
    Moneycontrol
    NewsBot
    Oct 11 1:48 PM
    Stocks in the news: Infosys, IndusInd Bank, TCS, Biocon, NCC, IOB, Tata Steel, BOI
    Moneycontrol
    NewsBot
    Oct 9 4:13 PM
    Strong support for Nifty at 11,000; HCL Tech, HDFC on analysts’ radar
    Moneycontrol
    NewsBot
    Oct 7 2:13 PM
    Podcast | Stock picks of the day: Nifty could find support around 11,050-10,800 levels
    Moneycontrol
    NewsBot
    Oct 7 1:18 PM
    A morning walk down Dalal Street | Avoid long positions, consider positional shorts on pull back towards 11,300
    Moneycontrol
    NewsBot
    Oct 5 5:33 PM
    DHFL, BPCL, Lakshmi Vilas Bank among 10 stocks that rose or fell the most in last week
    Moneycontrol
  • BIOCON - Related Communities

    keyboard_arrow_down
    MCX:RBDPMOLEIN
    MCX:PEPPER
    MCX:CASTORSEED
    MCX:CARDAMOM
    MCX:BRASSPHY
    Affle (India) Limited
    MCX:COTTON
    SPICEJET LTD Sector: Transport
    IRCTC Sector: Miscellaneous
    Share and discuss algorithms, strateg...
  • BIOCON - More Information

    keyboard_arrow_down

    Biocon Ltd:
    Biocon Limited is a biopharmaceutical firm in India, engaged in developing, manufacturing and selling pharmaceutical products for oncology, diabetes and autoimmune diseases in the nation as well as abroad. The company has several sectors of operations such as small molecules, branded formulations, research services and more.
    The company is manufacturing insulin lispro, insulin glargine, insulin aspart, recombinant human insulin, monoclonal antibodies, small molecules viz. generic formulations and active pharmaceutical ingredients and more, along with botanical products. Besides that, the company has branded formulation products under brands such as Insugen, BIOMAb, ALZUMAb, EGFR, Basalog and CANMAb. Biocon Limited has certifications such as ISO 9001, ISO 14001:2004, ISO 9001:2000, ISO 15189:2003 and OHSAS 18001:1999. The company has been developing its entire research system based upon small and large molecules, oligonucleotides and antibody-drug conjugates. Clinigene International Ltd and Syngene International Ltd are the two subsidiaries of Biocon Limited. The company has a global intervention in approximately 120 countries.
    About Company Information:
    Biocon Limited was incepted in 1978 and is headquartered in Bangalore, India. Biocon Limited was found when an Indian entrepreneur signed a joint venture with Ireland based firm Biocon Biochemicals Limited in 1978. The company started manufacturing and exporting enzymes to USA and Europe from 1979. Biocon Biochemicals Limited was acquired by Unilever plc and merged with Unilever’s subsidiary Quest International.
    In 1990, the company enhanced its in-house research programme by introducing new technologies. In 1993, the R&D, along with manufacturing facilities of the company, was certified ISO 9001 by RWTUV, Germany. Syngene International Pvt. Ltd was incorporated by the company in 1994 as a Custom Research Company for addressing the exponentially increasing need for outsourced Research & Development in the pharmaceutical sector.
    Developing an efficient manufacturing facility, Biocon Limited started to venture its initiatives for human healthcare in the medicine market and business since 1997. In 1998, Unilever had gone for a deal with ICI for selling its speciality chemicals division, which includes Quest International.
    A totally automated submerged fermentation plant, for the first time in its history of operation, was commissioned by the company in 2000, for manufacturing speciality pharmaceuticals. Clinigene, India’s first Clinical Research Organisation for providing clinical research and development was commissioned by the company in 2000. US FSA approved Biocon Limited as India’s first pharmaceutical company to manufacture the cholesterol-lowering molecule lovastatin.
    In 2005, a commercial agreement was signed by Biocon Limited for supplying insulin API to Asia, Africa and the Middle East. Nation’s largest biotechnology hub, having an integrated set up of manufacturing facilities and research laboratories with a spreading of 90 acres in Karnataka Industrial Areas Development Board—namely, Biocon Park was established by the company in 2006. Country’s largest multi-product Biologics facility was also established at Biocon Park.
    An MoU was signed between Biocon and Neopharma, resulting as a joint venture firm Neobiocon in July 2007. A strategic partnership was established between the company and IATRICa, Inc for developing jointly a range of immunoconjugates regarding the immunotherapy of cancers and infectious diseases in January 2008.
    BASALOG, long-lasting basal insulin for Type 1 & Type 2 Diabetics were introduced by Biocon Limited in 2009. Biocon Cell was launched as the resultant of the partnership between Biocon Limited and ISB for Innovation Management in the same year. AxiCorp GmbH, the German subsidiary of Biocon had been sold by the company in 2011, to its existing promoters and shareholders. ALZUMAb, was launched by Biocon Limited in 2013 for the psoriasis patients in India.
    In 2014, CANMAb – Trastuzumab, a medicine for the treatment of breast cancer was launched by the company in India. A world-class premium devices facility was inaugurated by Biocon at Bangalore in 2015 along with the introduction of Basalog One in India. Mylan and Biocon jointly submitted a proposal for Biosimilar Trastuzumab to USFDA in 2016.
    Biocon Limited declared that along with Mylan it is going to enhance the introduction of adalimumab biosimilar in Europe, as Mylan has an in-licensing arrangement with Fujifilm Kyowa Kirin Biologics.
    How Biocon Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Biocon Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Biocon Ltd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Advik Laboratories Ltd. ADVLAB
    Ahlcon Parenterals (India) Ltd. AHLPAR
    Ajanta Pharma Ltd. AJAPHL
    Aurobindo Pharma Ltd. AUROBP
    Bharat Immunological & Biologicals Corporation Ltd. BHAIMM
    Biofil Chemicals & Pharmaceuticals Ltd. BIOCHE
    Biowin Pharma (India) Ltd. BIOPHA
    Bliss GVS Pharma Ltd. BLIGVS
    Brabourne Enterprises Ltd.[Amalgamated] RPGLIF
    Brawn Biotech Ltd. BRAPHA
    Brooks Laboratories Ltd. BROLAB
    Cadila Healthcare Ltd. CADHEA
    Caplin Point Laboratories Ltd. CAPPOI
    Cipla Ltd. CIPLTD
    Claris Lifesciences Ltd. CORELA
    Colinz Laboratories Ltd. COLILA
    Combat Drugs Ltd. COMDRU
    Concord Drugs Ltd. CONDRU
    Coral Laboratories Ltd. CORLAB
    Desh Rakshak Aushdhalaya Ltd. DESRAK
    DIL Ltd. DILLIM
    Divi's Laboratories Ltd. DIVIL
    Dolphin Laboratories Ltd. DOLLAB
    Dr. Datsons Labs Ltd. AANLIF
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Ganga Pharmaceuticals Ltd. GANPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Ipca Laboratories Ltd. IPCLAB
    Ishita Drugs & Industries Ltd. ISHDRU
    J B Chemicals & Pharmaceuticals Ltd. JBCH
    Jagsonpal Pharmaceuticals Ltd. JAGPHA
    Jenburkt Pharmaceuticals Ltd. JENPHA
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Kabra Drugs Ltd. KABDRU
    Kamron Laboratories Ltd. KAMLAB
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Mangalam Drugs and Organics Ltd. MANDRU
    New Heaven Chemicals and Industries Ltd. TRAMED
    NGL Fine - Chem Ltd. NGLFIN
    Norris Medicines Ltd. NORMED
    Novartis India Ltd. NOVAIN
    Nutraplus India Ltd. NUTPRO
    Omega Labora.Ltd. OMELAB
    Oriental Remedies & Herbals Ltd. ORIREM
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Procter & Gamble Health Ltd. MERCLT
    Ranbaxy Laboratories Ltd. RANLAB
    RPG Life Sciences Ltd. RPGLI
    Rubra Medicaments Ltd. RUBMED
    Sanofi India Ltd. AVEPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Trans Asia Corporation Ltd. TRAASI
    Wockhardt Ltd. WOCLTD
    Wyeth Ltd. WYELTD
    Yogi Healthcare Ltd. COREHE
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.